Scholar Rock Holding Corp (SRRK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scholar Rock Holding Corp (SRRK) has a cash flow conversion efficiency ratio of -0.281x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.92 Million) by net assets ($245.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scholar Rock Holding Corp net asset quality index to measure how much of total assets are equity-financed.
Scholar Rock Holding Corp - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Scholar Rock Holding Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Scholar Rock Holding Corp reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Scholar Rock Holding Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scholar Rock Holding Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
APT Medical Inc
SHG:688617
|
0.098x |
|
Octave Intelligence plc
NASDAQ:OCTV
|
0.015x |
|
Eagers Automotive Ltd
AU:APE
|
-0.024x |
|
SYSMEX CORP.UNSP.ADR 1/2
F:0YX0
|
N/A |
|
Turkcell Iletisim Hizmetleri AS
NYSE:TKC
|
0.003x |
|
Resideo Technologies Inc
NYSE:REZI
|
-0.050x |
|
Dyno Nobel Ltd
AU:DNL
|
0.036x |
|
Sichuan Changhong Electric Co Ltd
SHG:600839
|
0.070x |
Annual Cash Flow Conversion Efficiency for Scholar Rock Holding Corp (2016–2024)
The table below shows the annual cash flow conversion efficiency of Scholar Rock Holding Corp from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Scholar Rock Holding Corp market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $368.63 Million | $-200.95 Million | -0.545x | +15.46% |
| 2023-12-31 | $225.22 Million | $-145.23 Million | -0.645x | -26.46% |
| 2022-12-31 | $260.24 Million | $-132.69 Million | -0.510x | +30.80% |
| 2021-12-31 | $172.07 Million | $-126.79 Million | -0.737x | -218.80% |
| 2020-12-31 | $260.77 Million | $-60.27 Million | -0.231x | +58.66% |
| 2019-12-31 | $112.90 Million | $-63.12 Million | -0.559x | -342.58% |
| 2018-12-31 | $106.62 Million | $24.57 Million | 0.230x | -43.26% |
| 2017-12-31 | $-53.52 Million | $-21.74 Million | 0.406x | -19.46% |
| 2016-12-31 | $-30.03 Million | $-15.14 Million | 0.504x | -- |
About Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to deve… Read more